A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Safety, Immunogenicity, and Efficacy of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis.

Trial Profile

A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Safety, Immunogenicity, and Efficacy of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ALLOW; ALLOW LTE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Sep 2011 Results published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top